IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerg
Travere Therapeutics
1 episodes
8 months ago
Listeners can expect to learn about:
• The disease burden and underlying pathophysiology of IgA nephropathy, including the role of endothelin and angiotensin in disease progression
• The current IgAN treatment landscape
• The response to sparsentan, a dual endothelin angiotensin receptor antagonist, in patients with IgA nephropathy in the phase 3 PROTECT trial
All content for IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerg is the property of Travere Therapeutics and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Listeners can expect to learn about:
• The disease burden and underlying pathophysiology of IgA nephropathy, including the role of endothelin and angiotensin in disease progression
• The current IgAN treatment landscape
• The response to sparsentan, a dual endothelin angiotensin receptor antagonist, in patients with IgA nephropathy in the phase 3 PROTECT trial
IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerg
Listeners can expect to learn about:
• The disease burden and underlying pathophysiology of IgA nephropathy, including the role of endothelin and angiotensin in disease progression
• The current IgAN treatment landscape
• The response to sparsentan, a dual endothelin angiotensin receptor antagonist, in patients with IgA nephropathy in the phase 3 PROTECT trial
